Completed PHASE3 INTERVENTIONAL 1-arm NCT00116922

A Lifestyle and Combination Medication Therapy Diabetes Prevention Study

CAnadian Normoglycemia Outcomes Evaluation Study

Sponsor: Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Conditions Diabetes Impaired Glucose Tolerance

Interventions Avandamet [Rosiglitazone 2mg/Metformin 500mg] BID

Updated 5 times since 2017 Last updated: May 22, 2012 Started: Jun 30, 2004 Primary completion: Jan 31, 2010 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Diabetes and Impaired Glucose Tolerance and is currently completed. Samuel Lunenfeld Research Institute, Mount Sinai Hospital leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Samuel Lunenfeld Research Institute, Mount Sinai Hospital
University of Western Ontario, Canada

Data source: Samuel Lunenfeld Research Institute, Mount Sinai Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, Canada
• Toronto, Canada